Chronic Condition Management
Latest News
July 18th 2025
An extensive global analysis led by Duke University challenges long-standing assumptions that reduced physical activity is to blame for rising obesity rates.
Clinical ShowCase™: Forming a Personalized Treatment Plan for a Patient With ANCA-Associated Vasculitis
View More
Addressing Healthcare Inequities: Tailoring Cancer Screening Plans to Address Inequities in Care
View More
SimulatED™: Diagnosing and Treating Alzheimer’s Disease in the Modern Era
View More
SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy
View More
Patient, Provider & Caregiver Connection™: Understanding the Patient Journey to Provide Personalized Care for Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
Clinical Consultations™: Addressing Elevated Phosphate Levels in Patients with END-STAGE Kidney Disease (ESKD)
View More
Advances In: Managing Hyperphosphatemia in Chronic Kidney Disease – Bridging Treatment Gaps With Novel Therapies
View More
Burst CME™: Addressing Inadequate Response to Anti-TNF Therapy in Patients With Rheumatoid Arthritis
View More
Community Practice Connections™: Cases and Conversations – Keeping Up with Novel Approaches to Managing ANCA-Associated Vasculitis
View More
Burst CME: Targeted Therapy for Optimal Psoriasis Management
View More
Cases and Conversations™: A Horizon View of Continuous Monitoring Systems for Diabetes Management
View More
More News
Medical aesthetic services: a host of opportunities and legal uncertainties
Published: June 21st 2024 | Updated: June 21st 2024A discussion of potential opportunities and legal risks that physicians and medical aesthetics business owners should be aware of going into the second half of 2024 and beyond.
Medicare's Alzheimer's math is fuzzy -- but critics are missing the bigger picture
May 14th 2024The Biden administration recently warned that Medicare could spend $3.5 billion on a new category of Alzheimer's drugs in 2025 alone – a figure vastly higher than what experts in the field predict – leading many to question the math.
